ENTXEntera Bio Ltd.
3.230USDMkt Cap: 559.25M $P/E: —3d ago
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase I…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap559.25M $
Enterprise Value548.36M $
Revenue (TTM)0 $
Gross Profit0 $
Net Income (TTM)-11.44M $
Revenue/Share0.0000 USD
Last Price3.230 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.87
PEG—
EV/EBITDA-38.16
EV/Revenue—
P/SInfinity
P/B14.10
EPS (TTM)-0.35
EPS (Forward)-0.55
52W Range
3.14045% of range3.340
52W High3.340 USD
52W Low3.140 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-27235.71%
ROE-87.31%
ROA-71.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.37M $
CapEx (TTM)107.00K $
FCF Margin—
FCF Yield-1.20%
Net Debt-10.88M $
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.04
Current Ratio8.98
Quick Ratio5.42
Book Value/Sh0.2290 USD
Cash/Share0.0650 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Upside (mean)+178.6%
Target Range9.000 USD – 9.000 USD
# Analysts1
Ownership
Shares Out.173.14M
Float121.49M
Insiders6.88%
Institutions34.20%
Short Interest
Short Ratio0.3d
Short % Float2.70%
Short % Out.2.33%
Shares Short1.15M
Short (prev mo.)332.66K
Technical
SMA 502.192 (+47.3%)
SMA 2001.739 (+85.7%)
Beta1.40
S&P 52W Chg19.18%
Avg Vol (30d)441.15K
Avg Vol (10d)432.28K
Technical Indicators
RSI (14)66.8
MACD0.2515
MACD Signal0.2676
MACD Hist.-0.0161
BB Upper3.527 USD
BB Middle3.020 USD
BB Lower2.513 USD
BB Width33.54%
ATR (14)0.2794 USD
Vol Ratio (20d)0.09x